Early Treatment of Language Impairment in Young Children With Autism Spectrum Disorder With Leucovorin Calcium

Phase 2Active Not RecruitingNCT04060017

Southwest Autism Research & Resource Center80 enrolled

Overview

The primary objective of this study is to evaluate the cognitive and behavioral effects of liquid leucovorin calcium on young children with autism spectrum disorder (ASD) and determine whether it improves language as well as the core and associated symptoms of ASD. The investigators will enroll 80 children across two sites, between the ages of 2.5 and 5 years, with confirmed ASD and known language delays or impairments. Participation will last approximately 26 weeks from screening to end of treatment.

Autism spectrum disorder (ASD) is a heterogeneous neurodevelopmental disorder with life-long consequences that affects young children during critical times in their development. ASD is defined by impairments in social-communication as well as the presence of restricted interests and repetitive behaviors. ASD is frequently associated with co-occurring language delays. Currently the only well-accepted treatment for core ASD symptoms is behavior therapy such as Applied Behavioral Analysis and Early Intensive Behavioral Intervention. There is no US Food and Drug Administration approved medical therapy that addresses core ASD symptoms or the pathophysiological processes that underlie ASD. The primary aim of this study is to evaluate the effect of a liquid form of leucovorin calcium on language impairments in very young children with ASD. Participants entered into the trial will have delayed social and communication abilities known to be associated with ASD. The investigators hypothesize that leucovorin calcium will significantly improve language as well as core and associated behavioral symptoms of ASD, and be well-tolerated with no significant adverse effects, in young children with ASD. The investigators further hypothesize that a combination of baseline cellular and genetic biomarkers will predict cognitive and behavioral response to the intervention. To assess whether the liquid form of leucovorin calcium is superior to placebo, the investigators will study 80 children across two sites, between the ages of 2.5 and 5 years, with confirmed ASD and known language delays at baseline. Participants will be randomly assigned to receive active treatment or placebo for 12 weeks under double-blind conditions. At the end of 12 weeks, all participants will receive active treatment for 12 weeks. Language skills, as well as specimen biomarkers, will be measured at screening and after each treatment arm in order to determine if the supplement positively influences language ability.

Study Type

INTERVENTIONAL

Eligibility

Sex: ALLMin age: 30 MonthsMax age: 60 Months

Medical Language ↔ Plain English

Inclusion Criteria: 1. Autism Spectrum Disorder (as defined below). 2. Between 2 years 6 months and 5 years 2 months of age at baseline 3. Language impairment (Ages and Stage Questionnaire between -1 and -3 SD for Language) 4. Has at least 4 month old expressive language ability as assessed by the MSEL Expressive Language Scale (i.e., Parent answers "yes" to " Voluntary babbling (such as 'bu, bu, bu")" Question #7 on the MSEL Expressive Language Scale. 5. English included in the languages in which the child is being raised 6. Autism severity of moderate or higher (≥4) under the 7-item clinical global impression-severity scale. Moderate level of autism severity (4) is defined by the diagnosis of ASD with language impairment, so fulfilling #1 and #4 fulfills this requirement. 6\. Ability to maintain all ongoing complementary, dietary, traditional, and behavioral treatments constant for the study period 7. Unchanged complementary, dietary, traditional, and behavioral treatments for two months prior to study entry Exclusion Criteria: 1. Known FRAA status by clinically validated test performed outside of research studies. 2. Mineral or vitamin supplementation that exceeds the Tolerable Upper Daily Intake Levels set by the Institute of Medicine (See Table 5 below) 3. Significant self-abusive or violent behavior or evidence of suicidal ideation, plan or behavior 4. Severely affected as defined by CGI-Severity Standard Score = 7 (Extremely Ill) 5. Severe prematurity (\<34 weeks gestation) as determined by medical history 6. Current uncontrolled gastroesophageal reflux 7. Current or history of liver or kidney disease as determined by medical history and safety labs 8. Genetic syndromes 9. Congenital brain malformations 10. Epilepsy 11. Any medical condition that the PI determines could jeopardize the safety of the study subject or compromise the integrity of the data 12. Significant negative reaction (i.e. fainting, vomiting, etc.) because of a previous blood draw. 13. Failure to thrive or Body Mass Index \< 5%ile or \<5%ile for weight (male \<11.2kg; female \<10.8kg by CDC 2000 growth charts) at the time of screening. 14. Concurrent treatment with drug that would significantly interact with l-leucovorin such as specific chemotherapy agents, antimalarial and immune suppressive agents and select antibiotics (See Table 6 below). 15. Allergy or Sensitivity to ingredients in the investigational product or placebo 16. Evaluation with the MSEL or BOSCC within 3 months of entering the study 17. Planned evaluation with the MSEL or BOSCC during the study

Outcomes

Primary Outcomes

Evaluate the change in measures of expressive language

Mullen Scales of Early Learning: a scale of cognitive abilities across the following domains: gross motor (not a core subscale), visual reception, fine motor, expressive language, and receptive language. Total change in expressive language ability will be measured by the change in the expressive language raw score. The expressive language domain is a 28-item scale with a raw score range of 0-50. Changes in expressive language raw scores will be reported. A higher raw score indicates a higher level of language ability.